Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
基本信息
- 批准号:10223236
- 负责人:
- 金额:$ 74.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptedAdoptionAnimal ModelAscitesBenignBiologicalBiological AssayBlood TestsCancer DiagnosticsCancer PatientCarcinomaCell Culture TechniquesCellsClinicalClinical ResearchCollectionComplexConsumptionCulture MediaCustomDevelopmentDevice DesignsDiagnosticEarly DiagnosisEnsureEnzyme-Linked Immunosorbent AssayEpithelial CellsEpithelial ovarian cancerExcisionGeneral HospitalsGenetic RiskGenetically Engineered MouseGoalsHospitalsHumanIndustryIndustry StandardLaboratoriesLeadLiquid substanceMalignant - descriptorMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMassachusettsMeasuresMedical DeviceMembraneMembrane ProteinsMethodsMicrofabricationModelingMolecularMolecular AnalysisMonitorMutationNanotechnologyNucleic AcidsOceansOperative Surgical ProceduresOutcomes ResearchOvarianOvaryPathogenesisPathologyPatientsPerformancePerinatalPeritonealPlasmaPreclinical TestingPreparationProtein AnalysisProteinsProtocols documentationQuality ControlReaderReproducibilityResourcesSamplingSampling BiasesScreening for Ovarian CancerScreening for cancerSerousSignal TransductionStandardizationStatistical Data InterpretationSystemSystems BiologyTP53 geneTechniquesTechnologyTestingThinkingTimeTranslatingTranslationsTumor BurdenUltracentrifugationValidationVariantVesicleWestern BlottingWomanadvanced diseaseassay developmentbasecancer carecancer cellcirculating biomarkersclinical diagnosticsclinical translationclinically relevantclinically translatablecomparativedesignearly detection biomarkersexosomeexperienceextracellular vesicleshigh risk populationhigh throughput technologyimprovedin-vitro diagnosticsindustry partnerinnovationinnovative technologiesinstrumentlaboratory equipmentliquid biopsyminimally invasivemultidisciplinarynanoplasmonicnanoscalenext generationnovelnovel markerparticleperipheral bloodpre-clinical researchpreclinical studyproduct developmentprophylacticprospectiveresearch clinical testingscreeningsensorsensor technologysuccesssurvivorshiptooltranslational impacttumor heterogeneitytumor progression
项目摘要
Extracellular vesicles (EVs) are a new class of circulating biomarker that promises non-invasive, real-time
cancer monitoring. Many studies have shown that i) EVs may function as reliable surrogates of parental cancer
cells, and ii) these vesicles can reflect global tumor burden, overcoming limitations of tumor heterogeneity and
sampling bias. Translating EV analyses into a clinically relevant cancer test, however, is limited by the lack of
standardized, practical methods. Conventional assay tools (e.g., ultracentrifugation, Western blotting, ELISA)
require large amounts of EVs and extensive processing, making them impractical for clinical workflows.
Moreover, variations in sample handling and testing protocols often lead to inconsistent and confounding
results. The goal of this proposal is to i) address such technical challenges in EV analyses, and ii) rigorously
evaluate EVs' clinical value as a novel biomarker for early detection of ovarian cancer. We formed a strategic
academic-industry partnership to achieve this goal: Exosome Diagnostics, an industry leader in EV-based
cancer diagnostics, offering ready capacity to develop and manufacture in-vitro diagnostic medical devices;
and the Center for Systems Biology at the Massachusetts General Hospital, a pioneer in developing novel
analytical technologies for EV analyses. These teams will bring their multidisciplinary expertise, innovative
technologies and complementary resources to carry out the following translational projects. First, we will
advance a standardized EV assay platform. We will adopt our recently developed ExoLution platform to
streamline EV collection, and the nPLEX (nano-plasmonic exosome) technology for high-throughput EV protein
screening. Our initial study showed that nPLEX achieved >1000-fold higher sensitivity than conventional
methods and yet consumed scant sample volumes (0.1 μL). We now seek to advance nPLEX to the instrument
level by i) improving its robustness and throughput, and ii) establishing standardized assay protocols.
Leveraging the developmental and regulatory expertise of Exosome Diagnostics, the resulting platform will be
ready for translation into clinical diagnostic laboratories. Second, we will perform a targeted clinical study,
particularly testing whether EVs can be exploited as a biomarker for early detection of ovarian cancer and
progression monitoring. Our preclinical study will use patient-derived ovarian cancer cells and novel genetically
engineered mouse models to identify EV protein signatures for ovarian cancer. We will next profile circulating
EVs from ovarian cancer patients and assess the correlation between tumor burden and EV protein signature.
Our study will be designed to ensure assay reliability and reproducibility, thereby delivering clinically
translatable EV diagnostics. We will impose stringent quality controls on device design and sample processing,
accrue well-annotated patient and control samples, and perform multisite testing. The technical and scientific
outcomes of this research could have a significant translational impact in cancer management, establishing
a robust, highly specific liquid biopsy for early detection of ovarian cancer.
细胞外囊泡(EVs)是一种新型的无创、实时的循环生物标志物
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cesar M Castro其他文献
Cesar M Castro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cesar M Castro', 18)}}的其他基金
Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array
利用高通量 OCEANA 扩大早期癌症检测 - 使用纳米等离子体阵列进行卵巢癌外泌体分析
- 批准号:
10762488 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
通过集成 CRISPR 和荧光核酸方法将 CODA 应用于宫颈癌筛查
- 批准号:
10647930 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10463778 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10686016 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10305371 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10684196 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10469368 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
- 批准号:
9982238 - 财政年份:2018
- 资助金额:
$ 74.67万 - 项目类别:
相似海外基金
How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
- 批准号:
2315783 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
- 批准号:
2719534 - 财政年份:2022
- 资助金额:
$ 74.67万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633211 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
- 批准号:
20K01113 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2436895 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633207 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Studentship
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
- 批准号:
426559561 - 财政年份:2019
- 资助金额:
$ 74.67万 - 项目类别:
Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
- 批准号:
2236701 - 财政年份:2019
- 资助金额:
$ 74.67万 - 项目类别:
Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
- 批准号:
19K01745 - 财政年份:2019
- 资助金额:
$ 74.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
- 批准号:
415543446 - 财政年份:2019
- 资助金额:
$ 74.67万 - 项目类别:
Research Fellowships